Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...

Eli Lilly and Company (NYSE:LLY) is a leading medicine company which discovers, develops, manufactures, and markets products ...

It has been corrected. A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their waists compared with Novo Nordisk’s rival ...

Though Eli Lilly and Novo Nordisk have recently taken steps to make their uber-popular GLP-1 drugs more affordable for ...

While the early week buzz centered around the U.S.-China trade agreement, another critical development unfolded quietly but ...

Shares of Septerna SEPN surged 51% on May 14 after the company entered into an exclusive global collaboration and license ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion. If the $12.50-per-share all-cash deal is completed, it will give ...

Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an $8 billion deal. Bayer first partnered with Loxo on the ...